Biofourmis, a Boston startup that makes technology to remotely monitor patients with chronic conditions and dangerous diagnoses, announced Thursday that it has taken in $100 million in new investment to help it advance products in the fields of cardiology, respiratory, oncology, and pain management.
The company, which moved to downtown Boston from Singapore last year, uses wearable sensors to understand patients’ vital signs and help doctors make decisions about their care from afar. This year, Biofourmis has also joined the battle against COVID-19, creating a system that uses artificial intelligence software to look for early signs of the viral illness.
Biofourmis CEO Kuldeep Singh Rajput said in an interview that the pandemic has helped show the value of remote monitoring technologies — not just for combating the coronavirus, but for other conditions that are generally evaluated through in-person visits. With many medical visits canceled or delayed to limit the spread of the virus, doctors and patients have been looking for ways to manage their conditions from a distance.
